CSBio CSBio

X
[{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Announces Publication of Positive Efficacy Data With Sitoiganap in Patients With Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Epitopoietic Research Corporation"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Partnering with Leading Academic Cooperative Groups to Study Amcenestrant in the Adjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Breast International Group"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"Dynacure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Flamingo Therapeutics"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"VLAIO","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics Receives \u20ac1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Flamingo Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The funding will advance Flamingo's RNA-targeting oncology portfolio, including translational research for its lead clinical program, AZD9150 (danvatirsen) in Phase II in head and neck squamous cell carcinoma, and preclinical work on its LncRNA program targeting MALAT-1.

            Lead Product(s): Danvatirsen,Pembrolizumab

            Therapeutic Area: Oncology Product Name: AZD9150

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: VLAIO

            Deal Size: $1.8 million Upfront Cash: Undisclosed

            Deal Type: Funding June 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The combined oncology company will advance Flamingo's lead programs, Danvatirsen (antisence oligonucleotide) in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting MALAT-1 in cancer.

            Lead Product(s): Antisence Oligonucleotide,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Danvatirsen

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Dynacure

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger March 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Gliovac (sitoiganap/ERC 1671) is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM,Such tumor tissue is then processed to obtain inactivated intact cells and disrupted lysed cells from different patients.

            Lead Product(s): Sitoiganap,GM-CSF,Cyclophosphamide

            Therapeutic Area: Oncology Product Name: Gliovac

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue standard therapy.

            Lead Product(s): Amcenestrant

            Therapeutic Area: Oncology Product Name: SAR439859

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients who have exhausted all other treatment options.

            Lead Product(s): Sitoiganap,Sargramostim,Cyclophosphamide

            Therapeutic Area: Oncology Product Name: Gliovac

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The MAA contains observations suggesting safety and efficacy of SITOIGANAP demonstrated from the interim data of a randomized double-blind phase II trial.

            Lead Product(s): Sitoiganap,Sargramostim,Cyclophosphamide

            Therapeutic Area: Oncology Product Name: ERC1671

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY